Keryx Biopharma (KERX) Releases Zerenex Abstracts Into ASN Meeting; Shares Rise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Roth Capital Boosts PT on Keryx (KERX) to $24; Recommends Buying Into ASN Meeting
October 16, 2013 12:21 PM EDTRoth Capital raises its price target on Buy-rated Keryx Biopharmaceuticals (Nasdaq: KERX) from $16 to $24 today.
Analyst Joseph Pantginis assigned a valuation to the potential of Zerenex in chronic kidney disease (CKD). He notes that abstracts American Society of Nephrology meeting will provide... More
